Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1391P - Phase III confirmatory efficacy and safety study of proposed bevacizumab biosimilar (MYL-1402O) compared with avastin, in the first-line treatment of patients with stage IV non-squamous non-small cell lung cancer (nsNSCLC)


17 Sep 2020


E-Poster Display


Mark Socinski


Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283


M.A. Socinski1, C. Waller2, T. Idris3, I. Bondarenko4, A. Luft5, K. Beckmann6, A. Vishweswaramurthy7, S. Loganathan7, G. Ranganna8, A. Barve9

Author affiliations

  • 1 Thoracic Oncology Program, Florida Hospital Advent Cancer Institute, 32803 - Orlando/US
  • 2 Haematology, Oncology, University Medical Centre Freiburg and Faculty of Medicine, Freiburg/DE
  • 3 Clinical Research, Mylan Pharmaceuticals Pvt Ltd, 560103 - Bengaluru/IN
  • 4 Haematology, Oncology, Municipal Institution City Clinical Hospital, 49102 - Dnipropetrovsk Oblast/UA
  • 5 Oncology, Leningrad Regional Clinical Hospital, Leningrad/RU
  • 6 Principal Statistician, Mylan Healthcare GmBH, 30173 - Hannover/DE
  • 7 Clinical Development &medical Affarirs, Biocon Biologics India LTD, 560100 - Bengaluru/IN
  • 8 Clinical Research, Mylan Pharmaceuticals Pvt Ltd, Bengaluru/IN
  • 9 Medical Affairs, Mylan Inc., Canonsburg/US


Abstract 1391P


MYL-1402O (MYL, proposed biosimilar to Avastin), has been developed and extensively characterized using state-of-the-art physicochemical and functional tests.


This was a multicenter, randomized, double blind, equivalence study to evaluate comparative efficacy and safety of MYL with Avastin in patients with Stage IV metastatic nsNSCLC. Patients received combination therapy of study treatment with carboplatin-paclitaxel (CP) up to 18 weeks (6 cycles) followed by 24 weeks (8 cycles) of monotherapy. The primary endpoint was overall response rate (ORR) at 18 weeks, based on RECIST 1.1 assessed by an independent review (IR) at any time point during the first 18 weeks. The equivalence margin for ratio of ORR (90% confidence interval [CI]) was 0.73, 1.36; and for difference in ORR (95% CI) was ± 12.5%. Sample size of 670 was determined adequate to evaluate equivalence. Key secondary endpoints included assessment of progression free survival (PFS), overall survival (OS), safety and immunogenicity up to 42 weeks.


671 patients (MYL: 337, Avastin: 334) were randomized. The ratio of ORR (90% CI) was 0.96 (0.83, 1.12) and the difference in ORR (95% CI) was -1.6 (-9.0, 5.9) between treatment arms. The CIs were within the pre-defined equivalence margin for ratio and difference in ORR. At Week 42, the median PFS (95% CI) in months for IR was 7.6 (7.0, 9.5) in MYL arm and 9.0 (7.2, 9.7) in Avastin arm (p = 0.0906); PFS for investigator assessment was 7.8 (7.0, 9.5) in MYL arm and 7.3 (7.0, 8.9) in Avastin arm (p = 0.4748). Median OS was not reached at 42 weeks; OS rate was 70.0% and 75.4% for MYL and Avastin, respectively (p = 0.1185). Safety was comparable between MYL and Avastin; Serious adverse events occurred in 17.6% vs. 16.7% with treatment related adverse events leading to death in 2.4% vs. 1.5% patients. The incidence of treatment emergent anti-drug antibodies (6.5% vs. 4.8%) was comparable between MYL and Avastin.


MYL is equivalent to Avastin, given in combination with CP, as measured by ORR. Other efficacy endpoints, safety and immunogenicity were comparable.

Clinical trial identification

EudraCT Number: 2015-005141-32.

Editorial acknowledgement

Legal entity responsible for the study

Mylan Pharmaceuticals Pvt. Ltd Bangalore, India Mylan Pharmaceuticals Pvt. Ltd Bangalore, India Mylan Pharmaceuticals Pvt. Ltd Bangalore, India.


Mylan Pharmaceuticals Pvt. Ltd Bangalore, India.


M.A. Socinski: Research grant/Funding (institution), Research Support: Spectrum ; Speaker Bureau/Expert testimony, Research grant/Funding (self): AZ; Speaker Bureau/Expert testimony, Research grant/Funding (self): Genentech; Speaker Bureau/Expert testimony: Lilly; Speaker Bureau/Expert testimony: Guardant; Speaker Bureau/Expert testimony: BMS; Speaker Bureau/Expert testimony: Bayer; Speaker Bureau/Expert testimony, Research grant/Funding (self): Novartis. C. Waller: Advisory/Consultancy: Mylan Inc. T. Idris: Full/Part-time employment: Mylan Pharmaceuticals PvT Ltd. K. Beckmann: Full/Part-time employment: Mylan. A. Vishweswaramurthy: Full/Part-time employment: Biocon Biologics . S. Loganathan: Full/Part-time employment, Holds ESOP: Biocon. G. Ranganna: Full/Part-time employment: Mylan Pharmaceuticals Pvt Ltd. A. Barve: Full/Part-time employment: Mylan Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings